ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells

作者：Elisa Bergaggio, Wei-Tien Tai, A. Aroldi, Carmen Mecca, Elisa Landoni, M. Nüesch, Ines Mota, J. Metovic, Luca Molinaro, Leyuan Ma, Diego Alvarado, C. Ambrogio, C. Voena, Rafael B Blasco, Tongqing Li, Daryl Klein, Darrell J. Irvine, Mauro Papotti, B. Savoldo, G. Dotti, R. Chiarle · 发表于：Cancer Cell · 年份：2023 · DOI：10.1016/j.ccell.2023.11.004 · 被引用次数：45 · 研究领域：Medicine

SUMMARY Selection of the best tumor antigen is critical for the therapeutic success of chimeric antigen receptor (CAR) T cells in hematologic malignancies and solid tumors. The Anaplastic Lymphoma Kinase (ALK) receptor is expressed by most neuroblastomas while virtually absent in most normal tissues. ALK is an oncogenic driver in neuroblastoma and ALK inhibitors show promising clinical activity. Here, we describe the development of ALK.CAR-T cells that show potent efficacy in monotherapy against neuroblastoma with high ALK expression without toxicity. For neuroblastoma with low ALK expression, combination with ALK inhibitors specifically potentiates ALK.CAR-T cells but not GD2.CAR-T cells. Mechanistically, ALK inhibitors impair tumor growth and upregulate the expression of ALK, thereby facilitating the activity of ALK.CAR-T cells against neuroblastoma. Thus, while neither ALK inhibitors nor ALK.CAR-T cells will likely be sufficient as monotherapy in neuroblastoma with low ALK density, their combination specifically enhances therapeutic efficacy.